UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.11955Principal InvestigatorMunster, Pamela
PhaseI (Cancer Control)
Age GroupAdultScopeLocal
TitlePhase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination with PCI24871 in Patients with Metastatic Solid Tumors
ObjectiveTo determine the safety and tolerability of the drug combination and to find a recommended Phase 2 dose.
Key Eligibility* Age: 18+ * Phase Ia: Patients must have histologically or cytologically documented metastatic solid tumor malignancies. * Phase Ib: Patients must have histologically or cytologically confirmed locally advanced, unresectable or metastatic sarcoma or renal cell carcinoma, any histologic subtype.
Applicable Disease SitesIll-Defined Sites
Therapies InvolvedChemotherapy multiple agents systemic
Drugs InvolvedGW786034 (Pazopanib)
PCI-24781
Pazopanib
Votrient (Pazopanib)
StatusOpen
Participating InstitutionsCTSI CRC Mt. Zion : Alyson Cockerill
ITI Early Phase Clinical Trials Unit : Alyson Cockerill
Mt. Zion : Alyson Cockerill
University of California San Francisco : Alyson Cockerill
Eligibility Document11955_CTGovEligibility_NCT01543763.doc
ContactAlyson Cockerill Phone:415-353-4091
Pager:
Email:CockerillA@cc.ucsf.edu